纳米技术与免疫治疗的相遇：对抗癌症的交叉对话

The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has revolutionized oncology, its efficacy remains constrained by the immunosuppressive tumor microenvironment (TME), off-target toxicity, and poor biodistribution of therapeutic agents.

This review elucidates how engineered nanoparticles (NPs) are redefining immune-oncology by enabling the precise delivery of immunomodulators, antigens, and genetic payloads to target cells, while reprogramming the TME to convert "cold" tumors into immunogenic "hot" landscapes.

A literature search was conducted using PubMed, Scopus, and Google Scholar. The review was performed in a narrative and non-systematic manner, focusing on studies addressing nanotechnology-enhanced cancer immunotherapy.

We dissect the physicochemical and functional versatility of NPs, emphasizing size-, charge-, and ligand-dependent strategies to enhance lymph node targeting, APC activation, and sustained cargo release. Innovations in metallic, lipid-based, and biomimetic NPs are highlighted, including gold and lipid-based NPs for enhanced immune responses. Furthermore, we explore combinatorial approaches, such as NP-mediated co-delivery of checkpoint inhibitors and chemotherapeutics, which amplify cytotoxic T-cell responses and mitigate systemic toxicity. Clinical advancements, including Nab-Paclitaxel and mRNA-loaded lipid NPs, underscore the translational potential of these platforms, with trials demonstrating improved survival and manageable adverse profiles.

However, challenges persist in optimizing targeting precision, scalability, and long-term safety. Integrating breakthroughs in material science, immunology, and bioengineering, this review charts a roadmap for next-generation nano-immunotherapies, advocating patient-specific designs and multimodal regimens. As the field strides toward clinical maturity, nanotechnology is poised to unlock the full potential of immunotherapy, paving the way for adaptive, immune-guided, and potentially curative cancer therapies.